Tirzepatide may cause slightly more headaches initially due to its dual receptor activation affecting both GLP-1 and GIP pathways in the brain simultaneously, though the data does not show a statistically significant difference between the two medications
"Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study"
From the first consultation to the post-operation follow-up, our team is dedicated to helping you achieve the silhouette you desire
10.1017/s0033291709992054 Psychol
If you're approved, your prescription goes to the compounding pharmacy, and your medication ships out within a few days
FDA has identified specific groups who face unacceptable health risks from GLP-1 therapy, and PlexusDx screens all patients to ensure safe eligibility before starting treatment